Showing results (51-60 of 185) with videos related to
Sort By:
Pageof 19
Critical Reviews in Oncogenesis|April 2, 2018
Targeting the Overexpressed YY1 in Cancer Inhibits EMT and MetastasisAnne Arah Cho, Benjamin BonavidaMolecular Cancer Therapeutics|December 17, 2002
X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO)Chuen-Pei Ng, Benjamin BonavidaAdvances in Cancer Research|October 11, 2002
A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistanceChuen-Pei Ng, Benjamin BonavidaInternational Journal of Oncology|October 25, 2008
Nitric oxide donors: novel cancer therapeutics (review)Sergio Huerta, Sapna Chilka, Benjamin BonavidaCells|February 26, 2026
The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune EvasionAnia Khachikian, Mai Ho, Benjamin BonavidaGenes & Cancer|August 16, 2018
Exosomes derived from cancerous and non-cancerous cells regulate the anti-tumor response in the tumor microenvironmentSusan Bae, Jeffrey Brumbaugh, Benjamin BonavidaCritical Reviews in Oncogenesis|April 2, 2018
The Forgotten YY2 in Reported YY1 Expression Levels in Human CancersSamantha Kaufhold, Nabil Aziz, Benjamin BonavidaCurrent Pharmaceutical Design|March 12, 2009
Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQAlina Katsman, Kazuo Umezawa, Benjamin BonavidaDrug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|February 20, 2007
Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agentAlina Katsman, Kazuo Umezawa, Benjamin BonavidaInternational Journal of Oncology|January 6, 2012
Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancerYoichi Mizutani, Yoji Katsuoka, Benjamin BonavidaPageof 19